Our results suggested that GAADPB model had higher sensitivity compared to the individual biomarkers (Figure 3), when we were detecting HCC subgroups with very early/early stage (BCLC 0/A), small size (diameter < 3 cm), single lesion, absent PPVT, absent metastases, AFP-negative (20 ng/ml) and DCP-negative (<40 ng/ml). This evidence concerns the gene ACE and hepatocellular carcinoma.